Ocugen develops gene therapies aimed at treating inherited retinal diseases and other conditions that cause vision loss. It last closed at $0.76 on Nov 17, down 2.11% on the day.
Only 1 firm rated OCGN in the past 90 days, not enough for a consensus
Average 12-month target
$9.50
▲ 1155.5% upside
Based on 1 analyst who set a price target on OCGN in the past 90 days. The average target is $9.50, with a high of $9.50 and a low of $9.50, compared with the last close of $0.76.
Low $9.50Avg $9.50High $9.50
Blue marker: last close $0.76
Highest target$9.50
Average target$9.50
Lowest target$9.50
Latest rating changes
HC Wainwright & Co.Maintained
Sep 10Buy$9.50
Canaccord GenuityMaintained
May 27Buy$11
Date
Firm
Action
Rating
Price target
Sep 10
HC Wainwright & Co.
Maintained
Buy
$9.50
May 27
Canaccord Genuity
Maintained
Buy
$11
Loading…
Technical Analysis
OCGN · as of the Nov 17 close · updated after every close
Downtrend
The stock is 7% below its 20 day and 21% below its 50 day average. It is 83% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 40). The nearest support is the Pivot S1 at $0.74, and the nearest resistance the Pivot at $0.76.
Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 10.7%/day
Key levels
$2.7352 week high+259.2%
$1.38200 day average+81.6%
$1.14100 day average+50.0%
$0.9150 day average+19.7%
$0.8120 day average+6.6%
$0.80Swing high (Oct 28)+5.3%
$0.77Pivot R1+1.3%
$0.76Pivot+0.0%
$0.76Last close
$0.74Pivot S1−2.6%
$0.70Swing low (Oct 26)−7.9%
$0.6952 week low−9.2%
Indicators
RSI (14)
40.50
Middle of its range
Neutral
MACD
-0.02
Below its signal line
Bearish
Stochastic
26.1
Middle of its range
Neutral
ADX (14)
23.0
Weak trend
Williams %R
-81.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-59.0
Oversold below −100, overbought above 100
Neutral
Rate of change
+0.3%
Change over 10 sessions
Bullish
ATR (14)
$0.08
Typical daily range, 10.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 24.9%/day
Key levels
$2.7352 week high+259.2%
$1.38200 day average+81.6%
$1.14100 day average+50.0%
$0.9150 day average+19.7%
$0.8120 day average+6.6%
$0.80Swing high (Oct 28)+5.3%
$0.77Pivot R1+1.3%
$0.76Pivot+0.0%
$0.76Last close
$0.74Pivot S1−2.6%
$0.70Swing low (Oct 26)−7.9%
$0.6952 week low−9.2%
Indicators
RSI (14)
36.55
Weak, oversold below 30
Neutral
MACD
-0.18
Below its signal line
Bearish
Stochastic
18.2
Near the bottom of its range
Oversold
ADX (14)
19.0
No clear trend
Williams %R
-91.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-106.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−25.8%
Change over 10 sessions
Bearish
ATR (14)
$0.19
Typical daily range, 24.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OCGN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how OCGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow OCGN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How OCGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OCGN is in one of them and how their past OCGN trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Ocugen
Ocugen is a company based in Malvern, Pennsylvania, that develops gene therapies for eye diseases. Its work centers on modifier gene therapies intended to treat inherited retinal diseases such as retinitis pigmentosa and Stargardt disease, as well as geographic atrophy, an advanced form of macular degeneration. The candidates are designed to be given as a single injection beneath the retina, with the aim of slowing vision loss in patients. The therapies are still in clinical development and are not yet approved for sale.